Kyowa Decision Spells End For Syndax’s Entinostat In Breast Cancer?

08 Oct 2021

Japanese firm's decision to end development of entinostat in its licensed territories marks possibly final blow to development of the HDAC inhibitor in breast cancer.

Breast cancer cell — Kyowa Kirin Ends Entinostat Development in breast cancer • Source: Alamy

Kyowa Kirin Co., Ltd. has decided to discontinue its development of the class I selective histone deacetylase (HDAC) inhibitor entinostat, to which it licensed exclusive development and commercialization rights in Japan and South Korea from originator Syndax Pharmaceuticals, Inc. for breast cancer use back in 2014.

Although it gave no specific reasons, the move came after what the Japanese firm described as “careful” consideration of the...